Conference Reports for NATAP

Back

IDSA Conference (Infectious Disease Society Association) San Diego, CA Oct 17-21 2012     Brief Interruption of HIV Antiretroviral Therapy in Patients with Preserved CD4 Count and Virologic Suppression is Safe and Well Tolerated - (11/01/12)   Lopinavir/Ritonavir Monotherapy Pilot Study: the MONDAKAL Study - (10/29/12)   Analysis of EVG/COBI/FTC/TDF Compared to EFV/FTC/TDF By Race in Treatment Naïve Patients - (10/29/12)   Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF in Patients with Adherence <95% and <90% - (10/29/12)   Simeprevir (TMC435) in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (PILLAR and ASPIRE Trials) - (10/23/12)   National trends in hospitalization and mortality for patients with HIV, HCV, or HIV/HCV co-infection: HCV Hospitalization Rates Increasing - (10/23/12)   Describing the Burden of Hepatitis C (HCV) in a large public health care system (Chicago); Initial response to the National Viral Hepatitis Action Plan - (10/23/12)   Correlates of HIV, HCV and HIV/HCV Co-Infection in a Northeastern Inner City Population - (10/22/12)   Recovery of Renal Function and Virologic Suppression Following Tenofovir Discontinuation - (10/22/12)   Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study - (10/22/12)   Inflammatory Biomarkers in HIV Patients in Vermont - (10/22/12)   Association Between Emergent Antiretroviral Drug Resistance and Baseline CD4 Cell Count in Treatment-Naive Patients Initiating Protease-Inhibitor-Based Therapy in Clinical Trials - (10/22/12)   HIV-infected adults with suppressed viremia on antiretroviral therapy have dysfunctional HDL that is associated with T cell activation - (10/22/12)   The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)   Effects of adherence and baseline viral load on virologic response, with resistance, dyslipidemia/lipodystrophy and bone mineral density analyses, among women compared to men in the Phase III Week 96 ECHO and THRIVE trials - (10/19/12)   The Pharmacokinetics of Telaprevir and Selected ART Medications in HCV/HIV Coinfected Patients - (10/19/12)   [poor] Quality of Hepatitis C care at an urban tertiary medical center - (10/19/12)